Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Collaboration streamlines patient access to oncology clinical trials
The deal includes upfront payments, milestone payments and ongoing royalties
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Subscribe To Our Newsletter & Stay Updated